For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View

Sponsor Spike Success.

Forte Biosciences Stock Soars Following $2.2 Billion Acquisition by Argenx

Jul 27, 2026
Forte Biosciences Stock Soars Following $2.2 Billion Acquisition by Argenx

Forte Biosciences saw its shares surge by 39.2% in pre-market trading following the announcement of a definitive agreement for its by Argenx, valued at approximately $2.2 billion. Under the terms of the all-cash deal, Argenx will pay $77 per share, which is about a 40% premium over Forte's last closing price. This offer also reflects an impressive 86% premium compared to Forte's volume-weighted average share price since the company disclosed positive results from its Phase 1b vitiligo trial on July 9, 2026.

The acquisition focuses on FB102, Forte's lead drug candidate, which is a first-in-class anti-CD122 antibody showing statistically significant results in treating vitiligo and celiac disease. This therapy aims to address autoimmune conditions that currently lack approved biologic treatments. Argenx stated that acquiring Forte will bolster its immunology pipeline by adding a promising clinical-stage asset with potential applications across various autoimmune diseases.

For Your Trading Desk
Trading Journals
Click For Trade View
Desk Accessories
Click For Trade View

Sponsor Spike Success.

The transaction builds on Argenx's previous strategic in Forte and has received unanimous approval from the boards of directors of both companies. It is anticipated to close in the third quarter of 2026 and will be fully financed using Argenx's existing cash resources.

This announcement comes shortly after Barclays initiated coverage on Forte Biosciences, giving it an Overweight rating and a price target of $74, indicating growing confidence in the commercial prospects of FB102. The broader equity market has also been favorable, with the S&P 500 rising by 0.9%, the Dow Jones Industrial Average increasing by 0.8%, and the Nasdaq advancing by 1.4%, reflecting a positive investor sentiment.

Interest in companies focused on autoimmune diseases remains strong, as larger pharmaceutical firms seek innovative assets to enhance their growth pipelines. With a fully financed cash offer of $77 per share, promising clinical data for FB102, and a supportive market environment, Forte Biosciences shares are trading just below the acquisition price, suggesting that investors are optimistic about the transaction's completion.

For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View
Trading Journals

Log entries, exits, and the reason you clicked. 'It looked promising' deserves a second look.

Click For Trade View

Sponsor Spike Success.

Recommended for You
Japan's Stock Market Faces Volatility Amid AI Investment Concerns
Breaking Market News Nov 10, 2026

Japan's Stock Market Faces Volatility Amid AI Investment Concerns

Japan's stock market is experiencing significant volatility as uncertainty surrounding artificial intelligence investments grows…

For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View
Trading Journals

Log entries, exits, and the reason you clicked. 'It looked promising' deserves a second look.

Click For Trade View
Desk Accessories

Monitor stands and desk organizers for a trading setup with fewer loose ends.

Click For Trade View
Market Microstructure & Order Flow

Books on liquidity, order books, spreads, and trade execution. A closer look at what happens between clicking and getting filled.

Click For Trade View
Algorithmic Trading & Python

Coding and research books for systematic traders. Backtests deserve scrutiny, not a victory lap.

Click For Trade View
Financial Statements & Earnings Research

References for reading earnings reports, cash flow, and balance sheets. The headline rarely brings all the footnotes.

Click For Trade View

Sponsor Spike Success.

Across our publications

In Other News

Latest stories from other publications.

Explore all publications (opens in a new tab)